Eli Lilly Stock Shows Market Leadership With Jump To 92 RS Rating

On Friday, Eli Lilly (LLY) reached a key performance benchmark, with its Relative Strength (RS) Rating climbing into the 90-plus percentile with an improvement to 92, up from 89 the day before.


When you’re researching the best stocks to buy and watch, keep a close eye on relative price strength. This exclusive rating from Investor’s Business Daily tracks share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock’s price behavior over the last 52 weeks stacks up against all the other stocks in our database.

Decades of market research reveals that the best stocks often have an RS Rating of above 80 as they begin their biggest runs.

Looking For Winning Stocks? Try This Simple Routine

Eli Lilly is trying to complete a flat base with a 335.43 entry. See if it can clear the breakout price in heavy volume. Be aware that it’s a third-stage base. Later-stage patterns can work, but have a greater failure rate since, by that point, the stock has already risen significantly.

Earnings Update

Eli Lilly reported negative growth for both sales and earnings last quarter. The next earnings report is still more than a month away.

Eli Lilly holds the No. 1 rank among its peers in the Medical-Diversified industry group. Danaher (DHR) and Johnson & Johnson (JNJ) are also among the group’s highest-rated stocks.

​Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks


Join IBD Live And Learn Top Chart-Reading And Trading Techniques From The Pros
MarketSmith’s Tools Can Help The Individual Investor
Profit From Short-Term Trends With SwingTrader
Get Timely Buy & Sell Alerts With IBD Leaderboard
Find The Best Long-Term Investments With IBD Long-Term Leaders

IBD Digital: Get access to subscriber-only stock lists and market analysis. Plus, add the weekly print edition for your weekend prep.

Leave a Comment